First Header Logo Second Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by Bayard Powell and Timothy Pardee.
Bayard Powell
Connection Strength
2.681
Timothy Pardee
  1. Pardee TS, Anderson RG, Pladna KM, Isom S, Ghiraldeli LP, Miller LD, Chou JW, Jin G, Zhang W, Ellis LR, Berenzon D, Howard DS, Hurd DD, Manuel M, Dralle S, Lyerly S, Powell BL. A Phase I Study of CPI-613 in Combination with High-Dose Cytarabine and Mitoxantrone for Relapsed or Refractory Acute Myeloid Leukemia. Clin Cancer Res. 2018 05 01; 24(9):2060-2073.
    View in: PubMed
    Score: 0.621
  2. Pardee TS, Lee K, Luddy J, Maturo C, Rodriguez R, Isom S, Miller LD, Stadelman KM, Levitan D, Hurd D, Ellis LR, Harrelson R, Manuel M, Dralle S, Lyerly S, Powell BL. A phase I study of the first-in-class antimitochondrial metabolism agent, CPI-613, in patients with advanced hematologic malignancies. Clin Cancer Res. 2014 Oct 15; 20(20):5255-64.
    View in: PubMed
    Score: 0.489
  3. Bouligny IM, Mehta V, Isom S, Ellis LR, Bhave RR, Howard DS, Lyerly S, Manuel M, Dralle S, Powell BL, Pardee TS. Efficacy of 10-day decitabine in acute myeloid leukemia. Leuk Res. 2021 Apr; 103:106524.
    View in: PubMed
    Score: 0.191
  4. Seegars MB, Woods R, Ellis LR, Bhave RR, Howard DS, Manuel M, Dralle S, Lyerly S, Powell BL, Pardee TS. A Pilot Phase II Study of the Feasibility and Efficacy of Vincristine Sulfate Liposome Injection in Patients With Relapsed or Refractory Acute Myeloid Leukemia. J Hematol. 2021 Feb; 10(1):1-7.
    View in: PubMed
    Score: 0.191
  5. Yates SJ, Lyerly S, Manuel M, Tooze JA, Klepin HD, Powell BL, Dralle S, Uprety A, Pardee TS. The prognostic value of standardized phase angle in adults with acute leukemia: A prospective study. Cancer Med. 2020 04; 9(7):2403-2413.
    View in: PubMed
    Score: 0.179
  6. Pardee TS, Luther S, Buyse M, Powell BL, Cortes J. Devimistat in combination with high dose cytarabine and mitoxantrone compared with high dose cytarabine and mitoxantrone in older patients with relapsed/refractory acute myeloid leukemia: ARMADA 2000 Phase III study. Future Oncol. 2019 Oct; 15(28):3197-3208.
    View in: PubMed
    Score: 0.174
  7. Ahmed T, Koch AL, Isom S, Klepin HD, Bishop JM, Ellis LR, Berenzon D, Howard D, Lyerly S, Powell BL, Pardee TS. Outcomes and changes in code status of patients with acute myeloid leukemia undergoing induction chemotherapy who were transferred to the intensive care unit. Leuk Res. 2017 11; 62:51-55.
    View in: PubMed
    Score: 0.152
  8. Ahmed T, Holwerda S, Klepin HD, Isom S, Ellis LR, Lyerly S, Manuel M, Dralle S, Berenzon D, Powell BL, Pardee TS. High dose cytarabine, mitoxantrone and l-asparaginase (HAMA) salvage for relapsed or refractory acute myeloid leukemia (AML) in the elderly. Leuk Res. 2015 Sep; 39(9):945-9.
    View in: PubMed
    Score: 0.129
  9. Tawfik B, Sliesoraitis S, Lyerly S, Klepin HD, Lawrence J, Isom S, Ellis LR, Manuel M, Dralle S, Berenzon D, Powell BL, Pardee T. Efficacy of the hypomethylating agents as frontline, salvage, or consolidation therapy in adults with acute myeloid leukemia (AML). Ann Hematol. 2014 Jan; 93(1):47-55.
    View in: PubMed
    Score: 0.115
  10. Klepin HD, Geiger AM, Tooze JA, Kritchevsky SB, Williamson JD, Pardee TS, Ellis LR, Powell BL. Geriatric assessment predicts survival for older adults receiving induction chemotherapy for acute myelogenous leukemia. Blood. 2013 May 23; 121(21):4287-94.
    View in: PubMed
    Score: 0.111
  11. Klepin HD, Geiger AM, Tooze JA, Kritchevsky SB, Williamson JD, Ellis LR, Levitan D, Pardee TS, Isom S, Powell BL. The feasibility of inpatient geriatric assessment for older adults receiving induction chemotherapy for acute myelogenous leukemia. J Am Geriatr Soc. 2011 Oct; 59(10):1837-46.
    View in: PubMed
    Score: 0.100
  12. Saad M, Loh KP, Tooze JA, Pardee TS, Ellis LR, Powell BL, Bhave RR, Geiger AM, Williamson JD, Kritchevsky S, Klepin HD. Geriatric assessment and survival among older adults receiving postremission therapy for acute myeloid leukemia. Blood. 2020 12 03; 136(23):2715-2719.
    View in: PubMed
    Score: 0.047
  13. Loh KP, Tooze JA, Nicklas BJ, Kritchevsky SB, Williamson JD, Ellis LR, Powell BL, Pardee TS, Goyal NG, Klepin HD. Inflammatory biomarkers, geriatric assessment, and treatment outcomes in acute myeloid leukemia. J Geriatr Oncol. 2020 04; 11(3):410-416.
    View in: PubMed
    Score: 0.042
  14. Kuhlman P, Isom S, Pardee TS, Burns C, Tawfik B, Lamar ZS, Powell BL, Klepin HD. Association between glycemic control, age, and outcomes among intensively treated patients with acute myeloid leukemia. Support Care Cancer. 2019 Aug; 27(8):2877-2884.
    View in: PubMed
    Score: 0.041
  15. Klepin HD, Tooze JA, Pardee TS, Ellis LR, Berenzon D, Mihalko SL, Danhauer SC, Rao AV, Wildes TM, Williamson JD, Powell BL, Kritchevsky SB. Effect of Intensive Chemotherapy on Physical, Cognitive, and Emotional Health of Older Adults with Acute Myeloid Leukemia. J Am Geriatr Soc. 2016 10; 64(10):1988-1995.
    View in: PubMed
    Score: 0.035
  16. Tawfik B, Pardee TS, Isom S, Sliesoraitis S, Winter A, Lawrence J, Powell BL, Klepin HD. Comorbidity, age, and mortality among adults treated intensively for acute myeloid leukemia (AML). J Geriatr Oncol. 2016 Jan; 7(1):24-31.
    View in: PubMed
    Score: 0.033
  17. Elliot K, Tooze JA, Geller R, Powell BL, Pardee TS, Ritchie E, Kennedy L, Callahan KE, Klepin HD. The prognostic importance of polypharmacy in older adults treated for acute myelogenous leukemia (AML). Leuk Res. 2014 Oct; 38(10):1184-90.
    View in: PubMed
    Score: 0.030
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.